Advertisement
Australia markets close in 1 hour 53 minutes

  • ALL ORDS

    7,853.80
    -83.70 (-1.05%)
     

  • ASX 200

    7,592.10
    -90.90 (-1.18%)
     

  • AUD/USD

    0.6524
    +0.0001 (+0.01%)
     

  • OIL

    83.85
    +0.28 (+0.34%)
     

  • GOLD

    2,346.80
    +4.30 (+0.18%)
     

  • Bitcoin AUD

    98,477.91
    +126.04 (+0.13%)
     

  • CMC Crypto 200

    1,388.61
    +6.04 (+0.44%)
     

  • AUD/EUR

    0.6082
    +0.0008 (+0.14%)
     

  • AUD/NZD

    1.0952
    -0.0006 (-0.05%)
     

  • NZX 50

    11,819.65
    -126.78 (-1.06%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    17,917.28
    -171.42 (-0.95%)
     

  • Hang Seng

    17,627.73
    +343.19 (+1.99%)
     

  • NIKKEI 225

    37,907.98
    +279.50 (+0.74%)
     

Monopar to Present at the Jefferies Radiopharma Innovation Summit

Monopar Therapeutics Inc.
Updated ·1-min read
Monopar Therapeutics Inc.
Monopar Therapeutics Inc.

WILMETTE, Ill., March 28, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will present at the Jefferies Radiopharma Innovation Summit next week.

Presentation Details:

Date: April 3, 2023
Time: 1:00 – 1:30 pm
Location: Jefferies Conference Center, NYC, New York

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for radiopharmaceutical use in advanced cancers; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: www.monopartx.com.

ADVERTISEMENT

CONTACT:

Monopar Therapeutics Inc.
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
kimtsu@monopartx.com

Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics